WorldPharmaNews
  • Home
  • Business
  • Research
  • Jobs
  • Events
  • Regulatory

Abbott

AbbottAt Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

www.abbott.com

Abbott RSS Channel

Filters
List of articles in category Abbott
Title Published Date
'Science' says Abbott is a Top Employer 30 October 2015
Abbott is asking one million people worldwide. Here's why and how. 22 September 2015
Abbott named industry leader for responsible and sustainable business for three consecutive years on the Dow Jones Sustainability Index (DJSI) 11 September 2015
Abbott completes acquisition of Veropharm 12 December 2014
Abbott to sell its developed markets branded generics pharmaceuticals business to Mylan 14 July 2014
Abbott to acquire Veropharm 23 June 2014
Abbott enhances its position in fast-growing Latin American market 18 May 2014
Abbott reports first-quarter 2014 results 16 April 2014
Abbott completes enrollment of Absorb™ randomized clinical trials in the United States, Japan and China 10 April 2014
Abbott reports fourth-quarter and full-year 2013 results 22 January 2014
Experience a day in the life of an insulin-using patient with diabetes through interactive infographic 14 November 2013
Abbott reports third-quarter 2013 results 16 October 2013
Abbott reports first-quarter 2013 results 17 April 2013
Abbott to collaborate with Janssen and Pharmacyclics 21 February 2013
Abbott initiates clinical trial of Absorb TM in the United States 08 January 2013
Abbott completes separation of research-based pharmaceuticals business 02 January 2013
Abbott announces three-year long-term data evaluating efficacy with HUMIRA® (Adalimumab) 22 October 2012
Abbott reports double digit earnings per share growth in the third quarter 17 October 2012
Abbott's HUMIRA® (adalimumab) receives FDA approval for the treatment of ulcerative colitis 30 September 2012
Abbott announces international launch of the Absorb(TM) 25 September 2012
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
  • End

Business & Industry

  • New set-up for IT at Bayer
  • Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
  • Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
  • Roche and Spark Therapeutics, Inc. announce extension of tender offer
  • AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations

Research & Development

  • High-tech method for uniquely targeted gene therapy developed
  • The new polymer can kill drug-resistant bacteria
  • A vaccine against chronic inflammatory diseases
  • Microcapsules for targeted drug delivery to cancer cells
  • Leukemia, lymphoma squarely in sights of new class of drugs
  • First investigational drug therapy for liver disease NASH awaiting FDA approval
  • The gut may be involved in the development of multiple sclerosis

Conferences & Events

  • Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
  • SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
  • SMi's 4th Annual 3D Cell Culture
  • Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
  • RNA Therapeutics Conference and Focus Day
  • CPhI Worldwide announces the winners of the 16th Pharma Awards
  • CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023

Regulatory Affairs

  • FDA launches app for health care professionals
  • FDA approves first generics of Gilenya
  • FDA approves novel treatment to target abnormality in sickle cell disease
  • FDA approves first treatment for inherited rare disease
  • FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
  1. You are here:  
  2. Home
  3. Abbott

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2006 - 2017. All Rights Reserved. WORLD PHARMA JOBS | PharmaNews.eu | eHealthNews.eu | (HEALTH IT) SPACE